Canaccord Genuity Keeps Their Hold Rating on IGO (IPGDF)
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Hoff covers the Basic Materials sector, focusing on stocks such as IGO, Pilbara Minerals , and ioneer Limited. According to TipRanks, Hoff has an average return of -1.8% and a 45.24% success rate on recommended stocks.
In addition to Canaccord Genuity, IGO also received a Hold from Morgan Stanley's Rahul Anand in a report issued on May 1. However, on the same day, Citi maintained a Buy rating on IGO (Other OTC: IPGDF).
Based on IGO's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $284 million and a GAAP net loss of $782.1 million. In comparison, last year the company earned a revenue of $408.6 million and had a net profit of $288.3 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is one of the . On July 28, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $105. The analyst highlighted a recent survey of healthcare professionals, which shows high expectations of a rapid adoption of the company's setmelanotide. The survey predicts a penetration rate of 51% by the third year of its launch. Ijem believes this presents significant upside for the company. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. Moreover, new dosing options like oral pills or once-weekly shots are also likely to increase setmelanotide's appeal as they are easier to administer compared to daily doses. The stock has already surged more than 54% this year and is trading close to its all-time high. Ijem believes there's more room for growth. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops precision medicines for rare genetic diseases of obesity. While we acknowledge the potential of RYTM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
11 hours ago
- Yahoo
Canaccord Genuity Initiates 'Buy' on Gold Fields (GFI) with $33 Target
Gold Fields Limited (NYSE:GFI) is one of the best stocks to buy amid gold rally. On July 28, Canaccord Genuity issued a 'Buy' rating as it initiated coverage on Gold Fields; it set the target price at $33. The investment bank cited strong near-term growth prospects for the South Africa-headquartered company. Gold Fields, a top-10 global gold producer operating 10 mines worldwide, is poised for near-term growth driven by expansions at Salares Norte and Gruyere through 2026, alongside ongoing development at Windfall and key assets like St Ives, South Deep, and Tarkwa through 2028. Canaccord Genuity projects notable deleveraging by 2027, which could bolster the company's capacity for M&A and support a re-rating of its shares through rising production, profits, and shareholder returns. Gold Fields Limited (NYSE:GFI) is a globally diversified gold mining company. It explores for, develops, and produces gold, with additional activities in copper and silver extraction. The company operates nine mines across South Africa, Australia, Ghana, Chile, and Peru, and owns the Windfall Project in Québec, Canada. Its primary product is gold bullion, refined from both underground and surface mining operations. While we acknowledge the potential of GFI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
19 hours ago
- Business Insider
Alphatec Holdings (ATEC) Gets a Buy from Canaccord Genuity
In a report released today, Caitlin Cronin from Canaccord Genuity maintained a Buy rating on Alphatec Holdings, with a price target of $20.00. The company's shares closed today at $13.77. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cronin is a 2-star analyst with an average return of 0.5% and a 45.74% success rate. Cronin covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Vericel, and Orthofix. In addition to Canaccord Genuity, Alphatec Holdings also received a Buy from Lake Street's Ben Haynor in a report issued today. However, on July 30, TR | OpenAI – 4o reiterated a Hold rating on Alphatec Holdings (NASDAQ: ATEC). Based on Alphatec Holdings' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $169.18 million and a GAAP net loss of $51.91 million. In comparison, last year the company earned a revenue of $138.48 million and had a GAAP net loss of $48.5 million Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATEC in relation to earlier this year. Most recently, in May 2025, Scott Lish, the COO of ATEC sold 12,000.00 shares for a total of $145,440.00.
